Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lofexidine + naltrexone is a combination of two pharmaceutical agents used primarily in the management of opioid dependence and withdrawal. Lofexidine is a centrally acting alpha-2 adrenergic receptor agonist that reduces the release of norepinephrine, thereby alleviating symptoms associated with acute opioid withdrawal such as muscle spasms, stomach cramps, insomnia, and anxiety[1][5][8]. Naltrexone is an opioid receptor antagonist that blocks the effects of opioids at their receptors and is used to prevent relapse after detoxification[2][4]. In some clinical settings—particularly in the United Kingdom—lofexidine has been combined with naltrexone for rapid detoxification protocols to manage both withdrawal symptoms (via lofexidine) and block opioid effects (via naltrexone)[6]. This combination does not treat addiction itself but facilitates safe discontinuation from opioids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lofexidine + naltrexone.